Marginal Zone Lymphoma in a case of Hidradenitis Suppurativa treated with Adalimumab therapy.

Authors

Anish K Shrestha, Department of Internal Medicine, MedStar Health Internal Medicine Residency Program, Baltimore, USA
Rojina Pokherel, Department of Internal Medicine, MedStar Health Internal Medicine Residency Program, Baltimore, USA,
Greeshma N Gaddipati, Department of Internal Medicine, MedStar Health Internal Medicine Residency Program, Baltimore, USA
Pankti S Desai, Department of Internal Medicine, MedStar Health Franklin Square Medical Center, Baltimore, USA,Follow

Abstract

Marginal zone lymphoma has seldom been described in relation to adalimumab used for treatment of hidradenitis suppurativa. Although studies have shown an increased risk of lymphoma with adalimumab, most of these studies were done in patients with underlying inflammatory bowel disease or rheumatoid arthritis where the disease itself presents as a confounder for lymphoma. Our case described adds to the role of chronic anti-TNF alpha therapy as a possible etiology of lymphoma.

Recommended Citation

Shrestha, Anish K; Pokherel, Rojina; Gaddipati, Greeshma N; and Desai, Pankti S () "Marginal Zone Lymphoma in a case of Hidradenitis Suppurativa treated with Adalimumab therapy.," Journal of Community Hospital Internal Medicine Perspectives: Vol. 15: Iss. 1, Article 12.
DOI: 10.55729/2000-9666.1444
Available at: https://scholarlycommons.gbmc.org/jchimp/vol15/iss1/12